The effect of jujube in management patients with non-alcoholic fatty liver

The effect of jujube on anthropometric , biochemical and hepatic steatosis predictors indices in patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140502017522N5

Enrollment

Registered

2023-06-07

Start date

2023-06-22

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Daily intake of 30 grams of jujube powder(Shaina Sharq Jujube company) ) for 12 weeks along with a low-calorie diet (500 kcal reduction). Intervention 2: Control gr

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: diagnosed patients with nonalcoholic fatty liver not abusing alcohol not having diabetes, kidney disorders and other liver diseases Not having liver cancer, or other cancers not having allergy to Jujube not taking multivitamins and minerals supplements during 3 month ago

Exclusion criteria

Exclusion criteria: pregnancy

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar (FBS). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.	—

Secondary

Measure	Time frame
Weight. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: scale.;Waist circumference. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: tape measure.;Body mass index. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard formula.;Aspartate aminotransferase (AST). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Enzyme-linked immuno_sorbent assay (ELISA).;Total cholesterol. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;High density lipoprotein. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;Low density lipoprotein. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;Triglyceride. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;Hepatic steatosis index(HS index). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: standard formula.;Fatty liver index(FL index). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: standard formula.;Triglyceride glucose index(TYG index). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention).	—

Measure

Time frame

Weight. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: scale.;Waist circumference. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: tape measure.;Body mass index. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard formula.;Aspartate aminotransferase (AST). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Enzyme-linked immuno_sorbent assay (ELISA).;Total cholesterol. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;High density lipoprotein. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;Low density lipoprotein. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;Triglyceride. Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: Standard enzymatic method.;Hepatic steatosis index(HS index). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: standard formula.;Fatty liver index(FL index). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention). Method of measurement: standard formula.;Triglyceride glucose index(TYG index). Timepoint: At the beginning of the study and after the intervention (12 weeks after the start of the intervention).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRonak Borzoei

Bagheiat-allah University of Medical Sciences

ronakborzooie@yahoo.com+98 83 2182 4025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026